| Host |
Mouse |
| Klon |
PG-M1 |
| Format |
Ready-to-use |
| Methode |
F, P |
| Vorbehandlung |
Fast Enzyme or other Enzymes |
| Positivkontrolle |
Tonsil |
| Verdünnung |
- |
| Isotyp |
Mouse IgG1 kappa |
| Lokalisation |
Cell Membrane |
CD68
|
Diagnostic Biosystems |
PG-M1 |
6 ml |
Ready-to-use |
CE/IVD |
PDM065 |
-
|
| Host |
Mouse |
| Klon |
KP1 |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Positivkontrolle |
Tonsil, lymph node, spleen. |
| Verdünnung |
1:100 - 1:200 |
| Isotyp |
IgG1 /κ |
| Verdünnung |
Subcellular fraction of human alveolar macrophages |
| Lokalisation |
Cytoplasm |
CD68
|
Zeta Corporation |
KP1 |
1.0 ml |
Concentrate |
CE/IVD |
Z2071ML |
-
|
| Host |
Mouse |
| Klon |
KP1 |
| Format |
Ready-to-use |
| Reaktivität |
- |
| Methode |
P |
| Positivkontrolle |
Tonsil, lymph node, spleen. |
| Verdünnung |
- |
| Isotyp |
IgG1 /κ |
| Verdünnung |
Subcellular fraction of human alveolar macrophages |
| Lokalisation |
Cytoplasm |
CD68
|
Zeta Corporation |
KP1 |
7 ml |
Ready-to-use |
CE/IVD |
Z2071MP |
-
|
| Host |
Mouse |
| Klon |
KP1 |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Positivkontrolle |
Tonsil, lymph node, spleen. |
| Verdünnung |
1:100 - 1:200 |
| Isotyp |
IgG1 /κ |
| Verdünnung |
Subcellular fraction of human alveolar macrophages |
| Lokalisation |
Cytoplasm |
CD68
|
Zeta Corporation |
KP1 |
0.5 ml |
Concentrate |
CE/IVD |
Z2071MS |
-
|
| Host |
Mouse |
| Klon |
KP1 |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Positivkontrolle |
Tonsil, lymph node, spleen. |
| Verdünnung |
1:100 - 1:200 |
| Isotyp |
IgG1 /κ |
| Verdünnung |
Subcellular fraction of human alveolar macrophages |
| Lokalisation |
Cytoplasm |
CD68
|
Zeta Corporation |
KP1 |
0.1 ml |
Concentrate |
CE/IVD |
Z2071MT |
-
|
| Host |
Mouse |
| Klon |
514H12 |
| Format |
TCS |
| Methode |
F, P |
| Vorbehandlung |
EDTA |
| Positivkontrolle |
Tonsil |
| Verdünnung |
1:40 - 1:80 |
| Isotyp |
Mouse IgG2a |
| Verdünnung |
Fusion protein corresponding to external domain of human CD68 |
CD68 (Macrosialin, Macrophage Antigen)
|
Zytomed Systems GmbH |
514H12 |
100 µl |
TCS |
RUO |
603-1332 |
-
|
| Host |
Rat |
| Klon |
FA-11 |
| Format |
Purified |
| Methode |
FL |
| Isotyp |
Rat IgG2a |
CD68 (Macrosialin, Macrophage Antigen) - FITC
|
Zytomed Systems GmbH |
FA-11 |
50 µg |
Purified |
RUO |
603-1333C |
-
|
| Host |
Mouse |
| Klon |
Ki-M7 |
| Format |
Purified |
| Methode |
FL |
| Isotyp |
Mouse IgG1 |
| Verdünnung |
Cell suspensions of human lymph node |
CD68 (Macrosialin, Macrophage Antigen) - FITC
|
Zytomed Systems GmbH |
Ki-M7 |
100 Tests |
Purified |
RUO |
603-1334C |
-
|
| Host |
Mouse |
| Klon |
H68.4 |
| Format |
Concentrate |
| Methode |
P |
| Vorbehandlung |
Citrate |
| Positivkontrolle |
Bone marrow |
| Verdünnung |
1:50 - 1:100 |
| Isotyp |
IgG1 |
| Lokalisation |
Cell membrane, cytoplasm |
CD71
|
Biocare Medical |
H68.4 |
0.1 ml |
Concentrate |
CD/IVD |
ACI3110A |
-
|
| Host |
Mouse |
| Klon |
H68.4 |
| Format |
Concentrate |
| Methode |
P |
| Vorbehandlung |
Citrate |
| Positivkontrolle |
Bone marrow |
| Verdünnung |
1:50 - 1:100 |
| Isotyp |
IgG1 |
| Lokalisation |
Cell membrane, cytoplasm |
CD71
|
Biocare Medical |
H68.4 |
0.5 ml |
Concentrate |
CD/IVD |
ACI3110B |
-
|
| Host |
Mouse |
| Klon |
H68.4 |
| Format |
Ready-to-use |
| Methode |
P |
| Vorbehandlung |
Citrate |
| Positivkontrolle |
Bone marrow |
| Verdünnung |
- |
| Isotyp |
IgG1 |
| Lokalisation |
Cell membrane, cytoplasm |
CD71
|
Biocare Medical |
H68.4 |
6 ml |
Ready-to-use |
CD/IVD |
API3110AA |
-
|
| Host |
Mouse |
| Klon |
ZM136 |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Positivkontrolle |
Spleen, bone marrow |
| Verdünnung |
1:100 - 1:200 |
| Isotyp |
IgG1/κ |
| Verdünnung |
Recombinant fragment of human TFRC receptor |
| Lokalisation |
Cytoplasm |
CD71
|
Zeta Corporation |
ZM136 |
1 ml |
Concentrate |
CE/IVD |
Z2685ML |
-
|
| Host |
Mouse |
| Klon |
ZM136 |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Positivkontrolle |
Spleen, bone marrow |
| Verdünnung |
- |
| Isotyp |
IgG1/κ |
| Verdünnung |
Recombinant fragment of human TFRC receptor |
| Lokalisation |
Cytoplasm |
CD71
|
Zeta Corporation |
ZM136 |
7 ml |
Concentrate |
CE/IVD |
Z2685MP |
-
|
| Host |
Mouse |
| Klon |
ZM136 |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Positivkontrolle |
Spleen, bone marrow |
| Verdünnung |
1:100 - 1:200 |
| Isotyp |
IgG1/κ |
| Verdünnung |
Recombinant fragment of human TFRC receptor |
| Lokalisation |
Cytoplasm |
CD71
|
Zeta Corporation |
ZM136 |
0.5 ml |
Concentrate |
CE/IVD |
Z2685MS |
-
|
| Host |
Mouse |
| Klon |
ZM136 |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Positivkontrolle |
Spleen, bone marrow |
| Verdünnung |
1:100 - 1:200 |
| Isotyp |
IgG1/κ |
| Verdünnung |
Recombinant fragment of human TFRC receptor |
| Lokalisation |
Cytoplasm |
CD71
|
Zeta Corporation |
ZM136 |
0.1 ml |
Concentrate |
CE/IVD |
Z2685MT |
-
|
| Host |
Mouse |
| Klon |
LN-2 |
| Format |
Concentrate |
| Methode |
F, P |
| Vorbehandlung |
Citrate |
| Positivkontrolle |
Tonsil |
| Verdünnung |
1:25 - 1:50 |
| Isotyp |
Mouse IgG1 kappa |
| Lokalisation |
Cell Membrane |
CD74
|
Diagnostic Biosystems |
LN-2 |
1 ml |
Concentrate |
CE/IVD |
MOB168 |
-
|
| Host |
Mouse |
| Klon |
LN-2 |
| Format |
Concentrate |
| Methode |
F, P |
| Vorbehandlung |
Citrate |
| Positivkontrolle |
Tonsil |
| Verdünnung |
1:25 - 1:50 |
| Isotyp |
Mouse IgG1 kappa |
| Lokalisation |
Cell Membrane |
CD74
|
Diagnostic Biosystems |
LN-2 |
0.1 ml |
Concentrate |
CE/IVD |
MOB168-01 |
-
|
| Host |
Mouse |
| Klon |
LN-2 |
| Format |
Concentrate |
| Methode |
F, P |
| Vorbehandlung |
Citrate |
| Positivkontrolle |
Tonsil |
| Verdünnung |
1:25 - 1:50 |
| Isotyp |
Mouse IgG1 kappa |
| Lokalisation |
Cell Membrane |
CD74
|
Diagnostic Biosystems |
LN-2 |
0.5 ml |
Concentrate |
CE/IVD |
MOB168-05 |
-
|
| Host |
Mouse |
| Klon |
LN-2 |
| Format |
Ready-to-use |
| Methode |
F, P |
| Vorbehandlung |
Citrate |
| Positivkontrolle |
Tonsil |
| Verdünnung |
- |
| Isotyp |
Mouse IgG1 kappa |
| Lokalisation |
Cell Membrane |
CD74
|
Diagnostic Biosystems |
LN-2 |
6 ml |
Ready-to-use |
CE/IVD |
PDM033 |
-
|
| Host |
Mouse |
| Klon |
LN-1 |
| Format |
Purified |
| Methode |
F, P, FL |
| Vorbehandlung |
Trypsin, Pronase |
| Positivkontrolle |
Human Tonsil |
| Isotyp |
Mouse IgM |
| Verdünnung |
Human lymphocytes and SU-DHL4 cell line |
CD75s
|
Zytomed Systems GmbH |
LN-1 |
1 ml |
Purified |
RUO |
603-1354 |
-
|
| Host |
Mouse |
| Klon |
HM57 |
| Format |
Concentrate |
| Methode |
F, P |
| Vorbehandlung |
Citrate |
| Positivkontrolle |
Tonsil |
| Verdünnung |
1:15 - 1:30 |
| Isotyp |
Mouse IgG1 |
| Lokalisation |
Cell Membrane |
CD79a
|
Diagnostic Biosystems |
HM57 |
1 ml |
Concentrate |
CE/IVD |
MOB118 |
-
|
| Host |
Mouse |
| Klon |
HM57 |
| Format |
Concentrate |
| Methode |
F, P |
| Vorbehandlung |
Citrate |
| Positivkontrolle |
Tonsil |
| Verdünnung |
1:15 - 1:30 |
| Isotyp |
Mouse IgG1 |
| Lokalisation |
Cell Membrane |
CD79a
|
Diagnostic Biosystems |
HM57 |
0.1 ml |
Concentrate |
CE/IVD |
MOB118-01 |
-
|
| Host |
Mouse |
| Klon |
HM57 |
| Format |
Concentrate |
| Methode |
F, P |
| Vorbehandlung |
Citrate |
| Positivkontrolle |
Tonsil |
| Verdünnung |
1:15 - 1:30 |
| Isotyp |
Mouse IgG1 |
| Lokalisation |
Cell Membrane |
CD79a
|
Diagnostic Biosystems |
HM57 |
0.5 ml |
Concentrate |
CE/IVD |
MOB118-05 |
-
|
| Host |
Mouse |
| Klon |
HM47/A9 |
| Format |
Concentrate |
| Methode |
F, P |
| Vorbehandlung |
Citrate |
| Positivkontrolle |
Tonsil |
| Verdünnung |
1:25 - 1:75 |
| Isotyp |
Mouse IgG1 kappa |
| Lokalisation |
Cell Membrane |
CD79a
|
Diagnostic Biosystems |
HM47/A9 |
1 ml |
Concentrate |
CE/IVD |
MOB242 |
-
|
| Host |
Mouse |
| Klon |
HM47/A9 |
| Format |
Concentrate |
| Methode |
F, P |
| Vorbehandlung |
Citrate |
| Positivkontrolle |
Tonsil |
| Verdünnung |
1:25 - 1:75 |
| Isotyp |
Mouse IgG1 kappa |
| Lokalisation |
Cell Membrane |
CD79a
|
Diagnostic Biosystems |
HM47/A9 |
0.1 ml |
Concentrate |
CE/IVD |
MOB242-01 |
-
|
| Host |
Mouse |
| Klon |
HM47/A9 |
| Format |
Concentrate |
| Methode |
F, P |
| Vorbehandlung |
Citrate |
| Positivkontrolle |
Tonsil |
| Verdünnung |
1:25 - 1:75 |
| Isotyp |
Mouse IgG1 kappa |
| Lokalisation |
Cell Membrane |
CD79a
|
Diagnostic Biosystems |
HM47/A9 |
0.5 ml |
Concentrate |
CE/IVD |
MOB242-05 |
-
|
| Host |
Mouse |
| Klon |
HM47/A9 |
| Format |
Ready-to-use |
| Methode |
F, P |
| Vorbehandlung |
Citrate |
| Positivkontrolle |
Tonsil |
| Verdünnung |
- |
| Isotyp |
Mouse IgG1 kappa |
| Lokalisation |
Cell Membrane |
CD79a
|
Diagnostic Biosystems |
HM47/A9 |
6 ml |
Ready-to-use |
CE/IVD |
PDM125 |
-
|
| Host |
Mouse |
| Klon |
HM47/A9 |
| Format |
Ready-to-use |
| Methode |
F, P |
| Vorbehandlung |
Citrate |
| Positivkontrolle |
Tonsil |
| Verdünnung |
- |
| Isotyp |
Mouse IgG1 kappa |
| Lokalisation |
Cell Membrane |
CD79a
|
Diagnostic Biosystems |
HM47/A9 |
25 ml |
Ready-to-use |
CE/IVD |
PDM125-25 |
-
|
| Host |
Rabbit |
| Klon |
SP18 |
| Format |
Ready-to-use |
| Reaktivität |
DG, PG, BV |
| Methode |
F, P |
| Vorbehandlung |
Citrate |
| Positivkontrolle |
Tonsil |
| Verdünnung |
- |
| Isotyp |
Rabbit IgG |
| Lokalisation |
Cell Membrane |
CD79a
|
Zytomed Systems GmbH |
SP18 |
6 ml |
Ready-to-use |
RUO |
RBG029 |
-
|
| Host |
Rabbit |
| Klon |
SP18 |
| Format |
Concentrate |
| Reaktivität |
DG, PG, BV |
| Methode |
F, P |
| Vorbehandlung |
Citrate |
| Positivkontrolle |
Tonsil |
| Verdünnung |
1:100 - 1:200 |
| Isotyp |
Rabbit IgG |
| Lokalisation |
Cell Membrane |
CD79a
|
Zytomed Systems GmbH |
SP18 |
1 ml |
Concentrate |
RUO |
RBK029 |
-
|
| Host |
Rabbit |
| Klon |
SP18 |
| Format |
Concentrate |
| Reaktivität |
DG, PG, BV |
| Methode |
F, P |
| Vorbehandlung |
Citrate |
| Positivkontrolle |
Tonsil |
| Verdünnung |
1:100 - 1:200 |
| Isotyp |
Rabbit IgG |
| Lokalisation |
Cell Membrane |
CD79a
|
Zytomed Systems GmbH |
SP18 |
0.5 ml |
Concentrate |
RUO |
RBK029-05 |
-
|
| Host |
Mouse |
| Klon |
MEM-233 |
| Format |
Purified |
| Methode |
WB, IP, FL |
| Isotyp |
Mouse IgG1 |
CD80
|
Zytomed Systems GmbH |
MEM-233 |
100 µg |
Purified |
RUO |
603-1373 |
-
|
| Host |
Rat |
| Klon |
RM80 |
| Format |
Purified |
| Methode |
F, FL |
| Isotyp |
Rat IgG2a |
| Verdünnung |
BCL1 cells expressing CD80 |
CD80
|
Zytomed Systems GmbH |
RM80 |
250 µg |
Purified |
RUO |
603-2340 |
-
|
| Host |
Mouse |
| Klon |
B-L2 |
| Format |
Purified |
| Methode |
F, FL |
| Isotyp |
Mouse IgG1 |
| Verdünnung |
CD82 transfected murine mastocytoma cell line P815 |
CD82
|
Zytomed Systems GmbH |
B-L2 |
200 Tests |
Purified |
RUO |
603-1390 |
-
|
| Host |
Mouse |
| Klon |
BU63 |
| Format |
Purified |
| Methode |
F, IP, FL |
| Isotyp |
Mouse IgG1 |
| Verdünnung |
Human peripheral blood lymphocytes |
CD86 (B7-2)
|
Zytomed Systems GmbH |
BU63 |
200 µg |
Purified |
RUO |
603-1396 |
-
|
| Host |
Mouse |
| Klon |
F15-42-1 |
| Format |
Purified |
| Methode |
F, IP, FL |
| Isotyp |
Mouse IgG1 |
| Verdünnung |
Purified human brain Thy-1 |
CD90 (Thy-1)
|
Zytomed Systems GmbH |
F15-42-1 |
200 µg |
Purified |
RUO |
603-1435 |
-
|
| Host |
Mouse |
| Klon |
OX-7 |
| Format |
Purified |
| Methode |
F, WB, FL |
| Isotyp |
Mouse IgG1 |
| Verdünnung |
Rat Thy-1 antigen |
CD90 (Thy-1)
|
Zytomed Systems GmbH |
OX-7 |
1 mg |
Purified |
RUO |
603-1439 |
-
|
| Host |
Mouse |
| Klon |
OX-7 |
| Format |
Purified |
| Methode |
FL |
| Isotyp |
Mouse IgG1 |
| Verdünnung |
Rat Thy-1 antigen |
CD90 (Thy-1) - FITC
|
Zytomed Systems GmbH |
OX-7 |
50 µg |
Purified |
RUO |
603-1446C |
-
|
| Host |
Mouse |
| Klon |
VIM-15b |
| Format |
Purified |
| Methode |
FL |
| Verdünnung |
1:5 |
| Isotyp |
Mouse IgG2b |
| Verdünnung |
MV4-11 acute monocyte leukaemai cells |
CD92 - FITC
|
Zytomed Systems GmbH |
VIM-15b |
100 µg |
Purified |
RUO |
603-2356 |
-
|
| Host |
Rabbit |
| Klon |
EP8 |
| Format |
Concentrate |
| Methode |
P |
| Vorbehandlung |
Citrate |
| Positivkontrolle |
Pancreas |
| Verdünnung |
1:100 - 1:200 |
| Isotyp |
Rabbit IgG |
| Verdünnung |
Synthetic peptide to residues on the C-terminus |
| Lokalisation |
Cell membrane, cytoplasm |
CD99
|
Biocare Medical |
EP8 |
0.1 ml |
Concentrate |
CE/IVD |
CME392A |
-
|
| Host |
Mouse |
| Klon |
HO36-1.1 |
| Format |
Concentrate |
| Methode |
F, P |
| Vorbehandlung |
Citrate |
| Positivkontrolle |
Sarcom |
| Verdünnung |
1:25 - 1:75 |
| Isotyp |
Mouse IgM |
| Lokalisation |
Cell Membrane |
CD99
|
Diagnostic Biosystems |
HO36-1.1 |
1 ml |
Concentrate |
CE/IVD |
MOB262 |
-
|
| Host |
Mouse |
| Klon |
HO36-1.1 |
| Format |
Concentrate |
| Methode |
F, P |
| Vorbehandlung |
Citrate |
| Positivkontrolle |
Sarcom |
| Verdünnung |
1:25 - 1:75 |
| Isotyp |
Mouse IgM |
| Lokalisation |
Cell Membrane |
CD99
|
Diagnostic Biosystems |
HO36-1.1 |
0.1 ml |
Concentrate |
CE/IVD |
MOB262-01 |
-
|
| Host |
Mouse |
| Klon |
HO36-1.1 |
| Format |
Concentrate |
| Methode |
F, P |
| Vorbehandlung |
Citrate |
| Positivkontrolle |
Sarcom |
| Verdünnung |
1:25 - 1:75 |
| Isotyp |
Mouse IgM |
| Lokalisation |
Cell Membrane |
CD99
|
Diagnostic Biosystems |
HO36-1.1 |
0.5 ml |
Concentrate |
CE/IVD |
MOB262-05 |
-
|
| Host |
Mouse |
| Klon |
HO36-1.1 |
| Format |
Ready-to-use |
| Methode |
F, P |
| Vorbehandlung |
Citrate |
| Positivkontrolle |
Sarcom |
| Verdünnung |
- |
| Isotyp |
Mouse IgM |
| Lokalisation |
Cell Membrane |
CD99
|
Diagnostic Biosystems |
HO36-1.1 |
6 ml |
Ready-to-use |
CE/IVD |
PDM106 |
-
|
| Host |
Rabbit |
| Klon |
EP8 |
| Format |
Ready-to-use |
| Methode |
P |
| Vorbehandlung |
Citrate |
| Positivkontrolle |
Pancreas |
| Verdünnung |
- |
| Isotyp |
Rabbit IgG |
| Verdünnung |
Synthetic peptide to residues on the C-terminus |
| Lokalisation |
Cell membrane, cytoplasm |
CD99
|
Biocare Medical |
EP8 |
6 ml |
Ready-to-use |
CE/IVD |
PME392AA |
-
|
| Host |
Mouse |
| Klon |
ZM139 |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Positivkontrolle |
Ewing’s sarcoma |
| Verdünnung |
1:100 - 1:200 |
| Isotyp |
IgG1 /κ |
| Verdünnung |
Recombinant fragment (around aa1-185) of human MIC2 protein (exact sequence is proprietary) |
| Lokalisation |
Cell surface |
CD99
|
Zeta Corporation |
ZM139 |
1 ml |
Concentrate |
CE/IVD |
Z2686ML |
-
|
| Host |
Mouse |
| Klon |
ZM139 |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Positivkontrolle |
Ewing’s sarcoma |
| Verdünnung |
- |
| Isotyp |
IgG1 /κ |
| Verdünnung |
Recombinant fragment (around aa1-185) of human MIC2 protein (exact sequence is proprietary) |
| Lokalisation |
Cell surface |
CD99
|
Zeta Corporation |
ZM139 |
7 ml |
Concentrate |
CE/IVD |
Z2686MP |
-
|
| Host |
Mouse |
| Klon |
ZM139 |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Positivkontrolle |
Ewing’s sarcoma |
| Verdünnung |
1:100 - 1:200 |
| Isotyp |
IgG1 /κ |
| Verdünnung |
Recombinant fragment (around aa1-185) of human MIC2 protein (exact sequence is proprietary) |
| Lokalisation |
Cell surface |
CD99
|
Zeta Corporation |
ZM139 |
0.5 ml |
Concentrate |
CE/IVD |
Z2686MS |
-
|
| Host |
Mouse |
| Klon |
ZM139 |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Positivkontrolle |
Ewing’s sarcoma |
| Verdünnung |
1:100 - 1:200 |
| Isotyp |
IgG1 /κ |
| Verdünnung |
Recombinant fragment (around aa1-185) of human MIC2 protein (exact sequence is proprietary) |
| Lokalisation |
Cell surface |
CD99
|
Zeta Corporation |
ZM139 |
0.1 ml |
Concentrate |
CE/IVD |
Z2686MT |
-
|
| Host |
Rabbit |
| Klon |
EP206 |
| Format |
Concentrate |
| Methode |
P |
| Vorbehandlung |
Citrate |
| Positivkontrolle |
Hairy cell leukemia |
| Verdünnung |
1:50 - 1:100 |
| Isotyp |
Rabbit IgG |
| Verdünnung |
Synthetic peptide corresponding to the residues of human CD103 protein |
| Lokalisation |
Cell membrane |
CD103
|
Biocare Medical |
EP206 |
0.1 ml |
Concentrate |
CE/IVD |
ACI3117A |
-
|